Can Qulipta Cause High Blood Pressure?
Qulipta (atogepant) does not directly cause hypertension according to its FDA prescribing information and clinical trial data, but clinicians should be aware that other CGRP-targeted therapies in the same drug class—specifically the monoclonal antibody erenumab—have shown postmarketing reports of new-onset or worsening hypertension. 1
Evidence from Clinical Trials
In the pivotal 12-week placebo-controlled trials of atogepant (Studies 1,2, and 3), hypertension was not listed among the adverse reactions occurring at ≥2% incidence. 2
The most common adverse events with atogepant were nausea (3–9%), constipation (2–8%), and fatigue/somnolence (4–5%), with no mention of blood pressure elevation as a significant safety signal. 2
A comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (2020–2024) covering 3,672 atogepant reports did not identify hypertension as a prominent adverse event signal for atogepant, in contrast to other gepants. 3
The phase 3 PROGRESS trial in chronic migraine (778 participants) similarly did not report hypertension as a treatment-emergent adverse event with atogepant 30 mg twice daily or 60 mg once daily. 4
Class-Wide Cardiovascular Considerations
Erenumab (a CGRP monoclonal antibody) has documented postmarketing reports of development or worsening of hypertension, prompting FDA revision of its prescribing information to include this warning. 1
The 2023 VA/DoD Headache Guideline explicitly states that "clinicians should be aware that some postmarketing studies have shown an increased risk for development or worsening of hypertension with erenumab." 1
A 2025 case report described variant angina (coronary vasospasm) in a 57-year-old woman with hypertension four days after starting atogepant 60 mg daily, suggesting that CGRP blockade may predispose vulnerable patients to vasospasm. 5 This represents a rare but serious cardiovascular event distinct from sustained hypertension.
Clinical Implications
Baseline cardiovascular risk assessment is prudent before initiating atogepant, particularly in patients with pre-existing hypertension, coronary artery disease, or multiple cardiovascular risk factors. 5
Monitor blood pressure during follow-up visits, especially in the first 3 months of therapy, given the class-wide signal with erenumab and the theoretical mechanism of CGRP antagonism reducing vasodilatory tone. 1, 5
If a patient develops new or worsening hypertension after starting atogepant, consider discontinuation and evaluation for alternative causes, as was done in the variant angina case. 5
The 2025 American College of Physicians guideline recommends atogepant as a second-line agent for episodic migraine prevention—reserved for patients who do not tolerate or inadequately respond to first-line therapies (beta-blockers, valproate, venlafaxine, or amitriptyline)—which inherently limits exposure in the broader migraine population. 6
Mechanism and Pathophysiology
CGRP is a potent vasodilator; its pharmacologic blockade may theoretically reduce compensatory vasodilation in patients with underlying vascular dysfunction, potentially unmasking or exacerbating hypertension or vasospasm. 5
Unlike erenumab (which targets the CGRP receptor), atogepant is a small-molecule CGRP receptor antagonist with different pharmacokinetic properties, which may explain the absence of a clear hypertension signal in clinical trials. 7, 8
Summary
While atogepant itself has not been associated with hypertension in controlled trials or large-scale pharmacovigilance data, the class-wide warning for erenumab and the isolated case of coronary vasospasm warrant cautious use in patients with cardiovascular comorbidities. Blood pressure monitoring during therapy is a reasonable precaution, particularly given the high prevalence of hypertension in the migraine population. 1, 5